drugset / Trial / NCT05173545

Clinical Pharmacokinetics of Mitoxantrone Hydrochloride Liposome Injection in Recurrent/Refractory Lymphoma Subjects

NCT05173545

Phase 1 Completed 24 enrolled CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
RandomizedParallel-groupOpen-labelTreatment

Summary

This is a single-center, open, randomized parallel group design study to investigate the pharmacokinetic characteristics of Mitoxantrone Hydrochloride liposome injection in the treatment of relapsed/refractory lymphoma after the first administration, and the safety and efficacy.

Timeline

Start
2019-07-29
Primary completion
2020-10-28
Completion
2020-10-28

Drugs

EvaluationDrugModalityDoseRoute
Subject Mitoxantrone Small molecule 12 mg/m2 Intravenous
Subject Mitoxantrone Small molecule 16 mg/m2 Intravenous
Subject Mitoxantrone Small molecule 20 mg/m2 Intravenous

Indications